Evidence map›Paper›PMID 40613200›Full record

ReviewInternational journal of oncology2025

Mohd Adnan Kausar, Khalid Farhan Alshammari, Fahaad Alenazi, Sadaf Anwar, Amany Mohammed Khalifa, Tarig Ginawi, Abdulaziz Asiri, Mohammad Zeeshan Najm, Syed Arman Rabbani, Mohamed El-Tanani and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mohd Adnan KausarDepartment of Biochemistry, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia.
Khalid Farhan AlshammariDepartment of Internal Medicine, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia.
Fahaad AlenaziDepartment of Pharmacology, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia.
Sadaf AnwarDepartment of Biochemistry, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia.
Amany Mohammed KhalifaDepartment of Pathology, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia.
Tarig GinawiDepartment of Biochemistry, College of Medicine, University of Ha'il, Hail 2440, Saudi Arabia.
Abdulaziz AsiriDepartment of Medical Laboratory Sciences, College of Applied Medical Sciences, University of Bisha, Bisha 67714, Saudi Arabia.
Mohammad Zeeshan NajmSchool of Biosciences, Apeejay Stya University, Gurugram, Haryana 122103, India.
Syed Arman RabbaniDepartment of Clinical Pharmacy and Pharmacology, RAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
Mohamed El-TananiRAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
Saumyatika GantayatSchool of Biosciences, Apeejay Stya University, Gurugram, Haryana 122103, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Maintaining genomic stability is essential for reducing the risk of carcinogenesis. Homologous recombination (HR) is a high‑fidelity DNA repair mechanism that addresses double‑strand breaks and interstrand crosslinks. The present review examined two key components of HR:

Indexed as

Breast NeoplasmsFanconi Anemia Complementation Group N ProteinOvarian NeoplasmsRad51 RecombinaseBiomarkers, TumorFemaleHomologous RecombinationHumansMutationPoly(ADP-ribose) Polymerase InhibitorsPrecision MedicineBiomarkers, TumorFanconi Anemia Complementation Group N ProteinPALB2 protein, humanPoly(ADP-ribose) Polymerase InhibitorsRAD51 protein, humanRad51 RecombinaseBRCAbreast cancergenetic testingHRRovarian cancerPALB2PARP inhibitorsRAD51theragnostic

Identifiers

PMID40613200
PMCPMC12270392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.